Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 9/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 9/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 9/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 9/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17351237 | 0.88 | MEN1 (0.41) | PDK1PDK2PDK3PDK4CHUK | |
| SCHEMBL4568245 | 0.87 | HDAC1 (0.41) | PDK1PDK2PDK3PDK4MEN1 | |
| SCHEMBL4568252 | 0.83 | PDK1 (0.38) | PDK1PDK2PDK3PDK4MEN1 | |
| SCHEMBL18874272 | 0.81 | MEN1 (0.41) | PDK1PDK2PDK3PDK4CHUK | |
| SCHEMBL4568240 | 0.81 | SMN1; SMN2 (0.41) | PDK1PDK2PDK3PDK4MEN1 | |
| SCHEMBL4568237 | 0.81 | KMT2A (0.48) | MEN1KMT2ALMNASMN1; SMN2KDM4E | |
| SCHEMBL23952225 | 0.80 | PDK1 (0.44) | PDK1PDK2PDK3PDK4CHUK | |
| SCHEMBL6582521 | 0.80 | CA1 (0.45) | MEN1KMT2ALMNACA1CA2 | |
| SCHEMBL31648042 | 0.79 | CA2 (0.46) | PDK1PDK2PDK3PDK4CA1 | |
| SCHEMBL7666909 | 0.79 | PDK1 (0.42) | PDK1PDK2PDK3PDK4CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | PDK1 4256/4885PDK2 2782/4885PDK3 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.